2.Yang, X et al. (2020) Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respiratory Medicine 8, 475–481.
4.Mcculloch, VCE (2007) Relaxing the rule of ten events per variable in logistic and cox regression. American Journal of Epidemiology 165, 710–718.
5.Huang, C et al. (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet (London, England) 395, 497–506.
6.Guan, WJ et al. Clinical characteristics of coronavirus disease 2019 in China. New England Journal of Medicine. Published online:28 Feb 2020. doi: 10.1056/NEJMoa2002032.
7.Novel Coronavirus Pneumonia Emergency Response Epidemiology Team (2020) The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China. Zhonghua Liu Xing Bing Xue Za Zhi 41, 145–151.
8.Chen, N et al. (2020) Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet (London, England) 395, 507–513.
9.Klekotka, RB, Mizgała, E and Król, W (2015) The etiology of lower respiratory tract infections in people with diabetes. Pneumonologia I Alergologia Polska 83, 401–408.
10.Allard, R et al. (2010) Diabetes and the severity of pandemic influenza A (H1N1) infection. Diabetes Care 33, 1491–1493.
11.Fu, Y, Cheng, Y and Wu, Y. Understanding Sars-cov-2-mediated inflammatory responses: from mechanisms to potential therapeutic tools. Virologica Sinica. Published online: 3 Mar 2020. doi: 10.1007/s12250-020-00207-4.
12.Pal, R and Bhansali, A (2020) COVID-19, diabetes mellitus and ACE2: the conundrum. Diabetes Research and Clinical Practice 162, 108132.
13.Geerlings, SE and Hoepelman, AI (1999) Immune dysfunction in patients with diabetes mellitus (DM). Fems Immunology and Medical Microbiology 26, 259–265.
14.Maddaloni, E and Buzzetti, R (2020) COVID-19 and diabetes mellitus: unveiling the interaction of two pandemics. Diabetes/Metabolism Research and Reviews. Published online: 31 Mar 2020. doi: 10.1002/dmrr.3321.
15.Mehta, P et al. (2020) COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet (London, England) 395, 1033–1034.
16.Hong, KH et al. (2018) Predictors of mortality in Middle East respiratory syndrome (MERS). Thorax 73, 286–289.
17.Choi, KW et al. (2003) Outcomes and prognostic factors in 267 patients with severe acute respiratory syndrome in Hong Kong. Annals of Internal Medicine 139, 715–723.
18.Zhou, F et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet (London, England). Published online: 9 March 2020. doi: 10.1016/S0140-6736(20)30566-3.
19.Bermejo-Martin, JF, Almansa, R and Lejarazu, RO (2013) Weakened immunity in aged hosts with comorbidities as a risk factor for the emergence of influenza A H7N9 mutants. Journal of Infection in Developing Countries 7, 497–498.
20.Yin, Y and Wunderink, RG (2018) MERS, SARS and other coronaviruses as causes of pneumonia. Respirology (Carlton, Vic.) 23, 130–137.
21.Shi, H et al. (2020) Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan. China: a descriptive study. Lancet Infectious Diseases 20, 425–434.
22.Liu, Y, Yang, Y and Xu, Y (2020) What we learned from SARS may provide important insights into understanding and management of the novel coronavirus disease 2019. Zhonghua Jie He He Hu Xi Za Zhi 43, 339–344.
23.Cheng, PKC et al. (2004) Viral shedding patterns of coronavirus in patients with probable severe acute respiratory syndrome. Lancet (London, England) 363, 1699–1700.
24.Xu, D et al. (2005) Persistent shedding of viable SARS-CoV in urine and stool of SARS patients during the convalescent phase. European Journal of Clinical Microbiology & Infectious Diseases 24, 165–171.
25.Corman, VM et al. (2016) Viral shedding and antibody response in 37 patients with Middle East respiratory syndrome coronavirus infection. Clinical Infectious Diseases 62, 477–483.
26.Oh, MD et al. (2016) Viral load kinetics of MERS coronavirus infection. New England Journal of Medicine 375, 1303–1305.
27.Hu, X et al. Factors associated with negative conversion of viral RNA in patients hospitalized with COVID-19. Science of the Total Environment. Published online: 22 Apr 2020. doi: 10.1016/j.scitotenv.2020.138812.
28.Yoon, YK et al. (2014) Impact of preceding respiratory viral infections on the clinical severity of patients with pneumococcal pneumonia. Influenza & Other Respiratory Viruses 8, 549–556.
29.Póvoa, P et al. (2020) C-reactive protein and albumin kinetics after antibiotic therapy in community-acquired bloodstream infection. International Journal of Infectious Diseases 95, 50–58.
30.Levitt, DG et al. (2016) Human serum albumin homeostasis: a new look at the roles of synthesis, catabolism, renal and gastrointestinal excretion, and the clinical value of serum albumin measurements. Journal of General Internal Medicine 9, 229–255.
31.Joseph, P et al. (2018) Pathogenicity and viral shedding of MERS-CoV in immunocompromised rhesus macaques. Frontiers in Immunology 9, 205.
32.Memish, ZA, Assiri, AM and Al-Tawfiq, JA (2014) Middle East respiratory syndrome coronavirus (MERS-CoV) viral shedding in the respiratory tract: an observational analysis with infection control implications. International Journal of Infectious Diseases 29, 307–308.
33.Wang, Y et al. (2018) Factors associated with prolonged viral shedding in patients with Avian influenza A(H7N9) virus infection. Journal of Infectious Diseases 217, 1708–1717.